⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 207 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 207 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
🇬🇧
💊 Medicine AT November 25, 2020

GAMMAGARD S/D Pulver und Lösungsmittel zur Herstellung einer Infusionslösung (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung)

📷 EU Safety Watch placeholder
GAMMAGARD S/D Pulver und Lösungsmittel zur Herstellung einer Infusionslösung (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung)
📷 EU Safety Watch placeholder
Gammagard S/D powder and solvent for infusion solution (powder and solvent for preparing an infusion solution) is subject to a parallel export ban.
🗄
Archived (older alert)
This alert was reported 2011 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.
📈 Timeline
11 days in total
May 18, 2026 May 29, 2026
Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? Gammagard is a medicine used as an infusion. It helps the body fight infections.

What's happening? There is not enough of this medicine in Austria right now.

Does this affect me? If you use Gammagard, your supply may be limited.

What should I do? Talk to your pharmacist or doctor about other options.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
Agency-published detail

🚫 Parallel export ban active · ATC: J06BA02 · Reason: Verknappung des Wirkstoffes · Marketing authorisation holder: Baxalta Innovations GmbH, Industriestraße 67, 1221 Wien, Österreich · BASG note: Es handelt sich hierbei um ein Verfahren gemäß § 4 Abs. 1 der Verordnung über die Sicherstellung der Arzneimittelversorgung. Der Bedarf der Patientinnen und Patienten im Inland kann mit dieser Arzneispezialität nicht gedeckt werden, obwohl nach Angaben des Zulassungsinhabers keine Einschränkung der Vertriebsfähigkeit vorliegt. · Affected packs: 1 Stück Durchstechflasche [verfügbar gemäß §4 (1), since 2020-11-25]

First published
November 25, 2020
Last refreshed by us
1 week ago
Severity (as classified)
Low
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

What is this medicine shortage alert about?
GAMMAGARD S/D Pulver und Lösungsmittel zur Herstellung einer Infusionslösung (Pulver und Lösungsmittel zur Herstellung einer Infusionslösung). Gammagard S/D powder and solvent for infusion solution (powder and solvent for preparing an infusion solution) is subject to a parallel export ban.
When was this alert issued?
This alert was issued on November 25, 2020 by BASG (Austria).
Which countries are affected?
The alert applies to Austria.
How serious is this alert?
Low risk. A low risk means harm is unlikely under normal use. The alert is informational but still worth reading.
What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.